{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T06:01:22Z","timestamp":1776060082774,"version":"3.50.1"},"reference-count":56,"publisher":"Korean Cancer Association","issue":"2","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203186"],"award-info":[{"award-number":["82203186"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["e-crt.org"],"crossmark-restriction":true},"short-container-title":["Cancer Res Treat"],"published-print":{"date-parts":[[2026,4,15]]},"abstract":"<jats:p>PurposeThis study aimed to evaluate the safety and efficacy of gemcitabine and cisplatin (GP) regimen in combination with immune checkpoint inhibitor sintilimab as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC) patients and the feasibility of the following selective bladder sparing surgery.Materials and MethodsPatients with histopathologically confirmed urothelial carcinoma without distant metastases (T2-4a, N \u2264 1, M0, American Joint Committee of Cancer 8th) and with adequate organ function will be enrolled. The therapeutic regimen was sintilimab 200 mg once on day 8, gemcitabine 1,000 mg\/m2 and cisplatin 35 mg\/m2 once on days 1 and 8, every 21 days for four cycles. The primary endpoint was pathologic complete response (pCR, pT0N0) rate. The secondary end points were ypT &lt; 2 rate, R0 resection rate, event-free survival, and safety.ResultsFrom May 4, 2020, to May 20, 2023, 55 patients were enrolled. Forty-six patients were evaluated for efficacy. Among the 42 patients who underwent surgery, 16 patients (38.0%) achieved pCR. Thirty-three patients (78.6%) achieved pT &lt; 2. With a median follow-up of 15.7 months, the 1-year event-free survival was 91.3%. Notwithstanding the poor pathological baseline characteristic of a high T3-T4a proportion (39.1%), a promising bladder preservation (including 22 patients transurethral resection of bladder tumor, 5 patients partial cystectomy, and 4 surveillances) rate was achieved (67.4%). The most common grade \u2265 3 treatment-related adverse events was neutropenia (n=15, 27.3%), which was related to chemotherapy. There were no grade 3 immune-related adverse events.ConclusionNeoadjuvant GP plus sintilimab is a promising regimen for MIBC patients, with relatively high pT &lt; 2 rate and triggering the emerging roles for the multi-disciplinary team decision-making for bladder sparing surgery.<\/jats:p>","DOI":"10.4143\/crt.2025.214","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T04:19:57Z","timestamp":1745813997000},"page":"581-590","update-policy":"https:\/\/doi.org\/10.4143\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Sintilimab Combined with Gemcitabine and Cisplatin for Muscle-Invasive Bladder Cancer Patients Followed by Selective Bladder Sparing Surgery: A Phase 2 Trial"],"prefix":"10.4143","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0572-9610","authenticated-orcid":true,"given":"Zhou","family":"Tong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4243-3894","authenticated-orcid":true,"given":"Guanghou","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hangyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xudong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lulu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuanwen","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijia","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5479-899X","authenticated-orcid":true,"given":"Peng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6667-0424","authenticated-orcid":true,"given":"Baiye","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2954","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(01)64487-2"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2020.01.007"},{"key":"ref3","first-page":"1042","volume-title":"Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial","author":"Bochner","year":"2015"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(05)64854-9"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.05.056"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.03.078"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010168"},{"key":"ref8","first-page":"1015","volume-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","author":"Bellmunt","year":"2017"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30616-2"},{"key":"ref10","first-page":"67","volume-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","author":"Balar","year":"2017"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2411"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.6_suppl.499"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.6_suppl.439"},{"key":"ref14","first-page":"3140","volume-title":"Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer","author":"Rose","year":"2021"},{"key":"ref15","first-page":"1312","volume-title":"Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial","author":"Funt","year":"2022"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5900"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(22)00439-3"},{"key":"ref18","first-page":"2363","volume-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","author":"Cercek","year":"2022"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.02.008"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003635"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068714"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00382-5"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2000.18.17.3068"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.07.757"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(10)70275-8"},{"key":"ref26","first-page":"325","volume-title":"Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival","author":"Fleischmann","year":"2014"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23848"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00252-7"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(18)30192-3"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.07.014"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.04.011"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31833"},{"key":"ref33","first-page":"859","volume-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","author":"Grossman","year":"2003"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.08.009"},{"key":"ref35","first-page":"202","volume-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","year":"2005"},{"key":"ref36","first-page":"931","volume-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","author":"Powles","year":"2021"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.08.024"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.012"},{"key":"ref39","first-page":"82","volume-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","author":"Witjes","year":"2021"},{"key":"ref40","first-page":"866","volume-title":"NCCN Guidelines(R) insights: bladder cancer, version 2.2022","author":"Flaig","year":"2022"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.04.086"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.09.030"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2014.11.007"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.08.023"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2020.02.10"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2020.03.04"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1590\/s1677-5538.ibju.2020.99.01"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041323"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2018.06.001"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3233\/blc-170134"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.15_suppl.4505"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.08.027"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.12.031"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1998.16.4.1298"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1996.01099.x"},{"key":"ref56","first-page":"2102","volume-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","author":"Bajorin","year":"2021"}],"container-title":["Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2025-214.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2025.214","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2025-214.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:32:04Z","timestamp":1776058324000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2025.214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"URL":"https:\/\/doi.org\/10.4143\/crt.2025.214","relation":{},"ISSN":["1598-2998","2005-9256"],"issn-type":[{"value":"1598-2998","type":"print"},{"value":"2005-9256","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"2025-02-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-28","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}